.png)
.png)
.png)
Upload Prescription
.png)
1 Strip = 10 Tablets
ACME laboratories LtdProduct Description
Sitagliptin and Metformin Hydrochloride is a potent fixed-dose combination therapy designed to improve glycemic control in adults with type 2 diabetes mellitus by leveraging two distinct, synergistic mechanisms of action. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by preventing the breakdown of incretin hormones like GLP-1; this increases insulin synthesis and release from pancreatic beta cells while simultaneously lowering glucagon secretion from alpha cells, thereby reducing hepatic glucose production in a glucose-dependent manner. Complementing this, Metformin, a biguanide, serves as an insulin sensitizer that primarily suppresses hepatic gluconeogenesis, decreases intestinal absorption of glucose, and enhances peripheral glucose uptake and utilization by improving insulin sensitivity in muscle and adipose tissue. Together, this dual-pathway approach targets the three core defects of type 2 diabetes—insulin deficiency, glucagon excess, and insulin resistance—leading to significant reductions in Hemoglobin A1c (HbA1c) without the high risk of hypoglycemia or weight gain often associated with other antidiabetic agents. The combination is typically administered twice daily with meals to mitigate common gastrointestinal side effects of Metformin, such as nausea or diarrhea, and it is contraindicated in patients with severe renal impairment due to the risk of lactic acidosis. Beyond its metabolic efficacy, the convenience of a single-tablet regimen significantly enhances patient adherence, which is critical for the long-term management of chronic hyperglycemia and the prevention of macrovascular and microvascular complications.
Similar Products
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
Previously Browsed Items
.jpg)
.jpg)
.png)
.jpg)
.jpg)
.jpg)
.jpg)
Copyright ﾃつｩ 2026 | Saf1 Rx | All rights reserved
.jpg)
.jpg)
